Endocrine-metabolic assessment checklist for cancer patients treated with immunotherapy: A proposal by the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE) and Italian Society of Pharmacology (SIF) multidisciplinary group

Immunotherapy has revolutionized tumour treatment by harnessing the power of the immune system to fight cancer. Anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (ipilimumab and tremelimumab), anti-programmed cell death protein 1 (PD-1) (nivolumab, pembrolizumab, cemiplimab, and dostarlimab), and anti-programmed death-ligand 1 (PD-L1) (atezolizumab, avelumab, and durvalumab) monoclonal antibodies are among the most widely used immunotherapeutic agents for a variety of malignancies [1,2].

Source: Cancer Treatment Reviews - April 3, 2024 Category: Cancer & Oncology Authors: Maria Chiara Zatelli, Antongiulio Faggiano, Antonella Argentiero, Romano Danesi, Stella D'Oronzo, Stefano Fogli, Tindara Franchina, Francesco Giorgino, Nicola Marrano, Dario Giuffrida, Stefania Gori, Giampiero Marino, Rossella Mazzilli, Matteo Monami, Mon Tags: Complications of Treatment Source Type: research